companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) Patient Website
    How will I receive ENHERTU? You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider ENHERTU is given 1 time every three weeks (21-day treatment cycle) Your healthcare provider will decide how many treatments you need
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
    Find valuable information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, [downloadable resources,] and more
  • HER2-positive mBC ENHERTU® (fam-trastuzumab deruxtecan-nxki)
    What is ENHERTU? ENHERTU is a prescription medicine used to treat adults who have human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment: for metastatic disease, or
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Results with ENHERTU
    What is ENHERTU? ENHERTU is a prescription medicine used to treat adults who have human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment: for metastatic disease, or
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Potential Side Effects
    Find information about potential side effects that may happen with ENHERTU® (fam-trastuzumab deruxtecan-nxki) and tips to help manage these side effects with your doctor
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | About ENHERTU
    ENHERTU is given as an intravenous (IV) infusion once every 3 weeks You will receive an ENHERTU infusion either at your oncologist's office or at a nearby infusion center
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
    ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment
  • ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Support and Resources
    What is ENHERTU? ENHERTU is a prescription medicine used to treat adults who have human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer